Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.9K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

3.1K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Hormonal Regulation01:33

Hormonal Regulation

37.4K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
37.4K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

1.6K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Elusive Search for Optimal Blood Pressure Targets.

Current hypertension reports·2017
Same author

A quarter-dose quadpill for initial treatment of hypertension.

Lancet (London, England)·2017
Same author

SPRINT: To Whom Do the Results Apply?

Journal of the American College of Cardiology·2016
Same author

Blood pressure target values: the saga continues.

European heart journal·2015
Same author

A Call for Appropriate Evidence and Outcomes-Based Use and Measurement of Anticoagulation for Atrial Fibrillation: Moving the Population Towards Improved Health Via Multiple Stakeholders.

Journal of managed care & specialty pharmacy·2015
Same author

Response to comment on "is addition of vasodilators to loop diuretics of value in the care of hospitalized acute heart failure patients? Real-world evidence from a retrospective analysis of a large United States hospital database".

Journal of cardiac failure·2015
Same journal

Neural Control of Tissue Perfusion: Emerging Evidence and Beyond.

Current hypertension reports·2026
Same journal

Correction to: Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
Same journal

Intersection of Pediatric Hypertension and Cardiovascular-Kidney-Metabolic Disease.

Current hypertension reports·2026
Same journal

Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?

Current hypertension reports·2026
Same journal

Leveraging the Electronic Health Record to Identify and Manage Resistant Hypertension.

Current hypertension reports·2026
Same journal

Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.6K

LCZ696: the next step in improving RAS inhibition?

Alan H Gradman1

  • 1Temple University School of Medicine (Clinical Campus), 1239 Shady Avenue, Pittsburgh, PA, 15232, USA, gradmanmd@aol.com.

Current Hypertension Reports
|April 3, 2015
PubMed
Summary
This summary is machine-generated.

LCZ696, a combination of valsartan and sacubitril, shows superiority over enalapril in heart failure patients. Further studies are needed to confirm its role in hypertension management and vascular protection.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.8K

Related Experiment Videos

Last Updated: Apr 15, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.6K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.8K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • LCZ696 is a novel drug combining valsartan (angiotensin receptor blocker) and sacubitril (neprilysin inhibitor).
  • The PARADIGM-HF trial demonstrated LCZ696's efficacy in heart failure with reduced ejection fraction.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of LCZ696 in hypertension.
  • To assess the potential of LCZ696 to displace existing renin-angiotensin system (RAS) blockers.

Main Methods:

  • Two large hypertension studies were conducted to assess LCZ696's antihypertensive effects.
  • Tolerability was compared to valsartan and placebo; potency was compared to amlodipine.

Main Results:

  • LCZ696 demonstrated potent and effective antihypertensive action.
  • Tolerability was similar to valsartan and placebo, with potency comparable to amlodipine.
  • No angioedema cases were reported in hypertension trials, though few Black patients were studied.

Conclusions:

  • LCZ696 shows promise as an antihypertensive agent.
  • Long-term outcome data and demonstration of renal and vascular protection are crucial for its adoption over current RAS blockers in hypertension.